Abstract

Background Abundant reports have uncovered an imbalance of Treg and Th17 cells in pulmonary diseases. Hereon, we intend to explore the impact of PARP-1 on the imbalance of Th17/Treg and the potential mechanism in premature rats with acute respiratory distress syndrome (ARDS). Methods Preterm ARDS infants and healthy term infants were enrolled in this investigation. To induce a rat model of ARDS, E.coli suspension was given to rats through two vaginal dilator-guided intramuscular injections. H&E staining was used to perform histopathological examination. Flow cytometry was employed to assess the proportion of Th17 or Treg cells accounted for CD4+ T cells. ELISA was applied to measure levels of IL-6, IL-17A, and IL-10 in the serum of ARDS patients. Moreover, the mRNA and protein expression levels of PARP-1, IL-6, IL-17A, and IL-10 were detected through qRT-PCR and western blotting. Results An increased Th17/Treg ratio was observed in preterm infants and rats with ARDS. The PARP-1 expression level was raised in the lung tissues of ARDS rats, and PARP-1 downregulation alleviated E.coli-induced lung injury in preterm rats. Expression levels of PARP-1, IL-6, and IL-17A were raised, and the IL-10 level was reduced in the lung tissues of rats after E.coli treatment, which was all reversed by PARP-1 suppression. Importantly, the ratio of Th17/Treg differentiated from purified CD4+ T cells of the E.coli + PARP-1 inhibitor group was elevated by recombinant IL-6. Conclusion PARP-1 downregulation repressed the imbalance of Th17 and Treg cells via reducing the expression level of IL-6, implying that PARP-1 may be a promising target for ARDS therapy.

Highlights

  • Acute respiratory distress syndrome (ARDS) is acknowledged to be a serious form of lung injury [1]

  • 17/Treg secretory cytokines were measured via Enzyme-Linked Immunosorbent Assay (ELISA), which showed that serum levels of IL-17A (P < 0.001) in cells and IL-10 (P < 0.05) in Treg cells were all boosted in acute respiratory distress syndrome (ARDS) infants compared to healthy controls (P < 0.001; Figure 1(c))

  • It turned out that mRNA and protein levels of PARP-1, IL-6, and IL-17A in the lung tissues of rats were raised and the IL-10 level was reduced in response to E.coli treatment (P < 0.01), which was partially reversed by PARP-1 suppression in the lung tissues of E.coli-induced pregnant rats (E18) and neonatal rats (P1) (P < 0.05; Figures 2(d) and 2(e)). erefore, we inferred that PARP-1 downregulation alleviated lung injury in E.coli-induced rats

Read more

Summary

Background

Abundant reports have uncovered an imbalance of Treg and 17 cells in pulmonary diseases. We intend to explore the impact of PARP-1 on the imbalance of 17/Treg and the potential mechanism in premature rats with acute respiratory distress syndrome (ARDS). An increased 17/Treg ratio was observed in preterm infants and rats with ARDS. E PARP-1 expression level was raised in the lung tissues of ARDS rats, and PARP-1 downregulation alleviated E.coli-induced lung injury in preterm rats. Expression levels of PARP-1, IL-6, and IL-17A were raised, and the IL-10 level was reduced in the lung tissues of rats after E.coli treatment, which was all reversed by PARP-1 suppression. The ratio of 17/Treg differentiated from purified CD4+ T cells of the E.coli + PARP-1 inhibitor group was elevated by recombinant IL-6. PARP-1 downregulation repressed the imbalance of 17 and Treg cells via reducing the expression level of IL-6, implying that PARP-1 may be a promising target for ARDS therapy

Introduction
Materials and Methods
Isolation of CD4+ T Cells
Analysis of 17 and Treg Cells via Flow Cytometry
Oxygenation Index (OI) resholds of Neonatal ARDS Rats
Leukocyte and Neutrophil Counts in BALF
2.11. Western Blot Analysis
2.12. Statistical Analysis
Results
PARP-1 Inhibition Alleviates Lung Injury in
PARP-1 Downregulation Reduces Imbalance of the 17/ Treg
Increased IL-6 Promotes 17/Treg Imbalance in the Lung Tissues of Rats
Findings
Discussion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call